Revvity Inc (RVTY)
OvervaluedFundamental
54
Price
$158.77
Market Cap
$17.48B
Part 1 · What the company is worth
Overview
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$2.91B
Trailing 12 months (through 7/5/2026)
Net Income
$238M
Trailing 12 months (through 7/5/2026)
Free Cash Flow
$509M
Total Equity
$7.25B
Total Liabilities
$4.92B
Current Ratio
1.80
Interest Coverage
3.82
Debt/EBITDA
4.39
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$102.51
Current Price
$158.77
Margin of Safety
-54.9%
Fair Value Range
$66.63 - $138.39
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
75.97
ROE
3.3%
P/B Ratio
2.45
P/FCF
31.74
Gross Margin
-
ROIC
2.6%
Profitability Radar
Value Creation (Economic Moat)
ROIC
2.6%
WACC
9.2%
ROIC − WACC
-6.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (15)
- EPS shows upward trend
- Price CAGR 11.30%
- P/B ratio 2.45
- Debt/equity ratio
- Operating margin 12.3%
- Positive free cash flow
- CapEx intensity
- Current ratio
- Interest coverage
- Debt/EBITDA
- Return on tangible assets
- Earnings surprise, average 6.1%
- Earnings quality (operating cash flow / net income) 2.64
- Share dilution -5.2%
- Piotroski F-Score 5/9
Failed (9)
- EPS CAGR 3.96%
- ROIC 2.6%
- P/FCF 31.74
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.3%
- Revenue growth 5Y -5.5%
- Net margin trend 8.2% vs 10.2%
Unavailable (3)
- Gross margin –
- Dividend payout –
- PEG ratio (needs P/E > 0 and growth > 0)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. Prahlad R. Singh Ph.D. | CEO, President & Director | 60 |
| Mr. Maxwell Krakowiak | Senior VP & CFO | 35 |
| Mr. Tajinder S. Vohra | Senior Vice President of Global Operations | 59 |
| Mr. Joel S. Goldberg | Senior VP of Administration, General Counsel & Secretary | 56 |
| Ms. Miriame Victor | Senior Vice President & Chief Business Officer | 44 |
| Ms. Anita Gonzales | Chief Accounting Officer, VP & Controller | 49 |
| Mr. Bryan A. Kipp | Senior VP of Technology & Licensing | - |
| Dr. Madhuri Hegde FACMG, Ph.D. | Senior VP & Chief Scientific Officer | - |
| Mr. Stephen Barr Willoughby | Senior VP of Investor Relations & Head of ESG | - |
| Ms. Magali Four | Senior VP and Chief People & Culture Officer | - |
Audit Risk
9
Board Risk
2
Compensation Risk
8
Shareholder Rights Risk
4
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-24
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-11
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-08-04
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much RVTY moves, measured on its daily prices.
More volatile than 52% of the tracked stocks (90-day volatility).
- Volatility 30d
- 39.5%
- Volatility 90d
- 37.3%
- Beta vs S&P 500 (1y)
- 1.15Correlation 0.38
- Max drawdown (12m)
- -30.1%
- ATR (14d, % of price)
- 3.70%
Earnings reactions
How RVTY moved around its past quarterly results.
Next earnings release
Nov 3, 2026 · In 10 days · Before the open
EPS estimate: 1.30Revenue estimate: $695M
What usually happens
- Over the last 12 releases the stock moved a median of 3.2% the next day, up or down.
- Next-day moves: up 6, down 6 (out of 12).
- Of the 4 releases that beat estimates, the stock fell the next day after 3.
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | During the session | 1.25 | 1.41 | +13.1% | -0.6% | -3.3% | +0.7% |
| May 5, 2026 | During the session | 1.04 | 1.06 | +2.3% | +3.1% | +6.7% | +14.4% |
| Feb 2, 2026 | During the session | 1.58 | 1.70 | +7.4% | -4.0% | -1.6% | -6.6% |
| Oct 27, 2025 | During the session | 1.16 | 1.18 | +1.7% | -4.1% | -1.7% | -5.4% |
| Jul 28, 2025 | During the session | n/a | n/a | n/a | -9.4% | -8.3% | -14.9% |
| Apr 28, 2025 | During the session | n/a | n/a | n/a | +7.4% | +0.8% | -0.3% |
| Jan 31, 2025 | During the session | n/a | n/a | n/a | -1.1% | -0.6% | -6.1% |
| Nov 4, 2024 | During the session | n/a | n/a | n/a | +1.2% | +3.1% | +1.2% |
| Jul 29, 2024 | During the session | n/a | n/a | n/a | +5.5% | +9.1% | +7.1% |
| Apr 29, 2024 | During the session | n/a | n/a | n/a | +1.9% | +3.5% | -0.9% |
| Feb 1, 2024 | During the session | n/a | n/a | n/a | +1.2% | +1.9% | -4.0% |
| Oct 30, 2023 | During the session | n/a | n/a | n/a | -17.2% | -16.1% | -9.9% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on RVTY and what the price did next.
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for RVTY.